Skip to main content
Login
Contact
Subscribe
Search form
Search
The Sweetwater Reporter
Home
Forms
News
Sports
Classifieds
Obituaries
Entertainment
Local Guide
Special Sections
Talking About...
Photos
Videos
Games
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Alnylam Pharmaceut
(NQ:
ALNY
)
83.12
USD
UNCHANGED
Streaming Delayed Price
/ Updated:
7:51 PM EST, Jan 18, 2019
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
0
Open
-
Bid (Size)
70.00 (1)
Ask (Size)
83.38 (1)
Prev. Close
83.12
Today's Range
83.12 - 83.12
52wk Range
60.27 - 153.99
Shares Outstanding
100,522,411
Dividend Yield
N/A
Performance
YTD
+14.24%
+14.24%
1 Month
+31.31%
+31.31%
3 Month
+10.90%
+10.90%
6 Month
-21.37%
-21.37%
1 Year
-36.55%
-36.55%
Top News
More News
New Research Coverage Highlights Gentex, Tenneco, Mercury General, MGM Resorts International, ResMed, and Alnylam Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2019
January 16, 2019
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Gentex Corporation...
Read More
from
GlobeNewswire News Releases
Alnylam Pharmaceuticals Prices Public Offering of Common Stock
January 14, 2019
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public...
Read More
from
Business Wire News Releases
More News
Read More
Alnylam Pharmaceuticals Announces Proposed Public Offering of Common Stock
January 14, 2019
from
Business Wire News Releases
Alnylam Announces Unaudited Fourth Quarter 2018 Global Revenues for ONPATTRO® (patisiran) and Provides Additional Commercial Updates
January 07, 2019
from
Business Wire News Releases
Alnylam to Webcast Presentation at 37th Annual J.P. Morgan Healthcare Conference
December 28, 2018
from
Business Wire News Releases
Alnylam Pharmaceuticals Larger Than S&P 500 Component PVH
January 17, 2019
category
Stocks
from
Market News Video
Thursday's ETF Movers: FBT, GDXJ
January 10, 2019
category
ETFs
from
ETF Channel
Alnylam Announces Settlement of Litigation with Silence Therapeutics
December 10, 2018
from
Business Wire News Releases
Interesting ALNY Put And Call Options For February 15th
January 03, 2019
category
Stocks
from
Market News Video
Why Dow Jones' Pfizer Is Prepped To Rival These 2 Biotech Stocks
January 14, 2019
from
Investor's Business Daily
Alnylam Pharmaceuticals Enters Oversold Territory (ALNY)
December 21, 2018
category
Stocks
from
Market News Video
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
